Table 1.

Changes of immunological function in two groups of patients (mean±SD).

Group	Case	CD3+ (%)	CD4+ (%)	CD8+ (%)	CD4+/CD8+	SIL-2R (U/mL)
Treatment group	30
Pre-		62.25±10.01a	36.83±10.44b	33.06±7.69b	1.24±0.65a	588.23±216.86b
Post-		68.31±9.72c	42.6±9.62c	29.24±6.25	1.66±0.85c	475.87±211.36c
Control group	30
Pre-		64.22±6.91a	35.62±7.49a	32.95±8.28a	1.17±0.43b	573.63±214.32b
Post-		60.63±5.75c	31.53±5.53c	37.14±7.48c	0.94±0.43c	692.17±221.33c
Normal	15	68.72±5.66	47.22±8.39	26.18±5.64	1.83±0.22	143.58±23.05

^aP<0.05,

^bP<0.01 vs normal control group;

^cP<0.05 vs pre-treatment.